Research Analysts Set Expectations for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst S. Corwin expects that the company will post earnings of $0.54 per share for the year. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other equities analysts also recently issued reports on the company. Roth Mkm increased their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday. JMP Securities started coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. Guggenheim assumed coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $9.03 on Friday. The stock has a fifty day moving average price of $7.97 and a 200 day moving average price of $6.44. Zevra Therapeutics has a 1-year low of $4.18 and a 1-year high of $9.21. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The company has a market cap of $475.14 million, a PE ratio of -4.58 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same period last year, the firm earned ($0.15) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP acquired a new stake in shares of Zevra Therapeutics during the third quarter worth $3,644,000. Stonepine Capital Management LLC bought a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $4,858,000. MetLife Investment Management LLC raised its stake in Zevra Therapeutics by 8.1% during the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after acquiring an additional 1,717 shares during the period. Rubric Capital Management LP bought a new position in Zevra Therapeutics in the third quarter worth about $139,000. Finally, Propel Bio Management LLC acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter worth approximately $1,248,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.